Cervical cancer is the fourth death related cancer in women worldwide. Stage-dependent therapies include surgery, chemotherapy, radiotherapy and chemoradiotherapy. However, therapy responses vary greatly in patients. We have previously shown that the presence of T helper 17 (Th17) cells in cervical cancer tissues, a specific type of immune cells, is associated with progression of the disease and a poor prognosis for the patients. Therefore, we are interested in the role of Th17 cells during cervical cancer therapy in search of novel immunotherapeutic approaches to improve personalization of cervical cancer therapy.

Here you can get further information.